The metabolic and bone density effects of continuous combined 17-beta estradiol and noresthisterone acetate treatments in Thai postmenopausal women: A double-blind placebo-controlled trial

Journal of the Medical Association of Thailand

Volumn 84, Issue 1, 2001, Pages 45-53

  Bunyavejchevin, S ^a   Limpaphayom, K K ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Estradiol; Lipid; Liver Function; Menopause; Noresthisterone

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; ESTRADIOL; GLOBULIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; NORETHISTERONE ACETATE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE METABOLISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENSITOMETRY; DOUBLE BLIND PROCEDURE; FEMALE; FEMUR NECK; GLUCOSE BLOOD LEVEL; HIP; HORMONAL THERAPY; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIVER FUNCTION; MAJOR CLINICAL STUDY; PHYSICAL EXAMINATION; POSTMENOPAUSE;

AGED; ANALYSIS OF VARIANCE; BONE DENSITY; DENSITOMETRY; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PROBABILITY; REFERENCE VALUES; THAILAND; TREATMENT OUTCOME;

EID: 0035028348     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Menopause and hormone replacement therapy: An overview
2. Amenorrhoea and endometrial atrophy with continuous oral estrogen and progestogen therapy in postmenopausal women
3. Estrogen-progestogen replacement in climacteric women, particularly as regards a new type of continuous regimen
4. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate
5. Norethindrone - A review of therapeutic applications
6. Magnitude and partern of skeletal response to long term continuous and cyclic sequential oestrogen/progestin treatment
7. Continuous oestrogen-progestrogen treatment and serum lipoprotein in postmenopausal women
8. Continuous combined and sequential estradiol and norethindrone acetate treatment of postmenopausal women: Effect of plasma lipoproteins in a two-year placebo-controlled trial
9. Increased binding of low density lipoprotein to liver membranes from rats treated with 17 alpha-ethinyl estradiol
10. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins
11. Lipid and carbohydrate metabolism studies in oophorectomized women: Effects produced by the addition of norethisterone acetate to two estrogen preparations
12. Comparison of transdermal and oral estrogen-progestin replacement therapy: Effects on serum lipids and lipoproteins
13. Oestrogens and atherosclerotic vascular disease - Lipid factors
14. Mechanism of hypertriglyceridaemia associated with contraceptive steroids
15. Long-term effects of oral and transdermal hormone replacement therapies on serum lipid and lipoprotein concentrations
16. Responses of HDL subclasses, Lp(A-I) and Lp(A-I:A-II) levels and lipolytic enzyme activities to continuous oral estrogen-progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women
17. Five years with continuous combined oestrogen/progestogen therapy. Effects on calcium metabolism, lipoproteins, and bleeding pattern
18. Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subfractions, and apolipoprotein A-I
19. Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women
20. Estrogen use and all-cause mortality. Preliminary results from the Lipid Research Clinics Program Follow-Up Study
21. Metabolic and hormonal effects of post-menopausal oestrogen replacement treatment. I. Glucose, insulin and human growth hormone levels during oral glucose tolerance tests
22. Cyclic changes in serum cholesterol and lipoproteins following different doses of combined postmenopausal hormone replacement therapy
23. L-norgestrel and progesterone have different influences on plasma lipoproteins
24. Effects of pharmalogical agents used during menopause: Impact onlipids and lipoproteins
25. Hormone replacement therapy and cardiovascular disease: Effects on plasma lipid risk markers
26. Metabolic regulation of apoproteins of high-density lipoproteins by estrogen and progesterone in the baboon (Papiosp)
27. Responses of HDL subclasses, Lp(A-I) and Lp(A-I:A-II) levels and lipolytic enzyme activities to continuous oral estrogen-progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women
28. A two-year double-blind controlled study of the clinical effect of combined and sequential postmenopausal replacement therapy and steroid metabolism during treatment
29. Metabolic risk factors for coronary heart disease in women: Perspective from the Framingham Study
30. Estrogen replacement and cardiovascular disease: Serum lipids and blood pressure effects
31. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-up Study
32. Pathogenesis of osteoporosis
33. 17 Beta-estradiol and continuous norethisterone: A unique treatment for established osteoporosis in elderly women
34. Continuous low-dose oestrogen and progestogen hormone replacement therapy: A randomised trial
35. Uncoupling of bone formation and resorption by combined oestrogen and progestagen therapy in postmenopausal osteoporosis
36. Effects of norethisterone on bone related biochemical variables and forearm bone mineral in post-menopausal osteoporosis
37. Magnitude and pattern of skeletal response to long term continuous and cyclic sequential oestrogen/progestin treatment
38. Effects of one-year hormone replacement therapy on peripheral bone mineral content in patients with osteoporotic spine fractures
39. Effect of 17 beta-oestradiol and norethisterone acetate on vertebral bone mass and lipid metabolism in early postmenopausal women
40. Continuous oestrogen-progestogen treatment and bone metabolism in post-menopausal women